Cite
HARVARD Citation
Nemoto, O. et al. (2016). The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study. British journal of dermatology. pp. 296-304. [Online].